Dermatomycoses of the glabrous skin: A double-blind, randomised, comparative trial of sertaconazole 2% cream once daily versus vehicle

Clinical Drug Investigation

Volumn 23, Issue 6, 2003, Pages 387-394

  Susilo, Rudy ^a   Korting, Hans C ^b   Strauss, Uwe Phillip ^a  

^a Trommsdorff GmbH/Co Arzneimittel   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SERTACONAZOLE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYCOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FUNGUS CULTURE; GLABROUS SKIN; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SKIN BURNING SENSATION; TREATMENT OUTCOME;

EID: 0038648815     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323060-00002     Document Type: Article

References (16)

1. Bastert J, Korting HC. Tinea in glabrous skin: total quality management. Z Arztl Fortbild Qualitatssich 1998; 92: 181-6
2. Noble SL, Forbes RC, Stamm PL. Diagnosis and management of common tinea infections. Am Fam Physician 1998; 58: 163-74
3. Palacin C, Sacristan A, Ortiz JA. In vitro activity of sertaconazole. Arzneimittelforschung 1992; 42: 689-774
4. Torres J, Marquez M, Camps F. Sertaconazole in the treatment of mycoses: from dermatology to gynecology. Int J Gynaecol Obstet 2000; 71: 3-20
5. Nasarre J, Umbert P, Herrero E, et al. Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of pityriasis versicolor. Arzneimittelforschung 1992; 42: 764-7
6. Umbert P, Nasarre J, Bello A, et al. Phase II study of the therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of superficial mycoses caused by Candida albicans. Arzneimittelforschung 1992; 42: 757-60
7. Pedragosa R, Gonzales B, Martin M, et al. Therapeutic efficacy and safety of the new sertaconazole in the treatment of cutaneous dermatophytoses. Arzneimittelforschung 1992; 42: 760-3
8. Alomar C, Bassas S, Casas M, et al. Multicentre double-blind trial on the efficacy and safety of sertaconazole cream 2% in comparison with miconazole 2% cream on the patients suffering from cutaneous mycoses. Arzneimittelforschung 1992; 42: 767-73
9. Meinhof W, Girardi RM, Stracke A. Patient noncompliance in dermatomycosis: results of a survey among dermatologists and general practitioners and patients. Dermatologica 1984; 169 Suppl. 1: 57-66
10. Korting HC. Comparative efficacy and tolerability of econazole liposomal gel 1%, conventional cream 1% and generic clotrimazole cream 1% in tinea pedis. Clin Drug Invest 1997; 14: 286-93
11. Del Palacio A, Cuetara S, Perez A, et al. Topical treatment of dermatophytosis and cutaneous candidosis with flutrimazole 1% cream: double-blind, randomized comparative trial with ketoconazole 2% cream. Mycoses 1999; 42: 649-55
12. Evans EG, Seaman RA, James IG. Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections. Br J Dermatol 1994; 130: 83-7
13. Evans EG, Dodman B, Williamson DM, et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. BMJ 1993; 307: 645-7
14. Korting HC, Tietz HJ, Brautigam M, et al. One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. LASINT-06 Study Group. Med Mycol 2001; 39: 335-40
15. Farre M, Ugena JM, Marquez M, et al. Pharmacokinetics and tolerance of sertaconazole in man after repeated percutaneous administration. Arzneimittelforschung 1992; 42: 752-4
16. Romaguera C, Herrero E, Marquez M, et al. Study on the sensitizing capacity of the new antimycotic sertaconazole in the treatment of cutaneous mycoses. Arzneimittelforschung 1992; 42: 754-6